Phase II study of chemoradiotherapy with docetaxel for elderly patients with stage II / III esophageal carcinoma

Abstract

INTERVENTION: Chemoradiaion(Docetaxel+RT) CONDITION: Esophageal cancer PRIMARY OUTCOME: 2‐years survival SECONDARY OUTCOME: Complete Response Rate, ; Progression free survival,; Adverse Events,; Late Adverse Events INCLUSION CRITERIA: patients must fulfill all of the following criteria to be eligible for the trial 1 thoracic esophageal cancer 2 histologically confirmed squamous cell carcinoma or adenocarcinoma or adenosquamous carcinoma 3 clinical stage from II to III except T4 4 patient do not receive any previous therapy for esophageal cancer and previous chemotherapy for any other malignancy 5 age from 70 to 80 years 6 ps of 0 and 1 7 patient do not want to receive esophagectomy 8 adequate organ funcion 9 no evidence to need treatment of ECG within 28 days prior to entering this study 10 written informed consent